BetterLife Pharma Inc BETR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CA$0.23
- Day Range
- CA$0.21–0.23
- 52-Week Range
- CA$0.04–0.46
- Bid/Ask
- CA$0.21 / CA$0.22
- Shares Outstanding
- 618.01M
- Market Cap
- CA$129.78M
- Volume/Avg
- 467,301 / 360,207
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BetterLife Pharma Inc is an emerging biotechnology company focused on developing and commercializing the compound BETR-001 to treat neuropsychiatric and neurological disorders. BETR-001 is a non-hallucinogenic and non-controlled LSD derivative in development, and it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles, and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder, and other neuropsychiatric and neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
Valuation
|
Metric
|
BETR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BETR
|
|---|---|
Quick Ratio | 0.11 |
Current Ratio | 0.21 |
Interest Coverage | −16.24 |
Quick Ratio
BETR
Profitability
|
Metric
|
BETR
|
|---|---|
Return on Assets (Normalized) | −394.51% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BETR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^xcrT!! | LOCK|grh^V | $127B | |||
| Moderna Inc
MRNA
| LOCK|&#@F&Y& | LOCK|wCW | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K#KMLx | LOCK|&^d^p | $81B | |||
| argenx SE ADR
ARGX
| LOCK|D!V&NH | LOCK|h% | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bl!S#WZ | LOCK|!S> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#?G%<&M | LOCK|<b<^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|y<WGC>! | LOCK|zv>ly | $27B | |||
| Incyte Corp
INCY
| LOCK|?@SxcYC | LOCK|h^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|lns^G<F | LOCK|>?F | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|s%XsB> | LOCK|xf? | $14B |
United States